Why the study?
The prognostic value of mixed venous oxygen tension (PvO 2 ) at pulmonary hypertension diagnosis treated with selective pulmonary vasodilators remains unclear.
Does tissue hypoxia (PvO2 < 35 mmHg) predict poorer long-term survival in patients with PAH and CTEPH?
Does tissue hypoxia (PvO2 < 35 mmHg) predict poorer long-term survival in patients with PAH and CTEPH?
Tissue hypoxia (PvO2 < 35 mmHg) at diagnosis is a significant predictor of poor long-term survival in patients with PAH and medically treated CTEPH.
No takes yet. Share an insight, caveat, or question.
PvO2 <35 mmHg was associated with poorer survival in PAH/CTEPH; hypothesis-generating for its role in risk stratification.
Nagata et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: